JPRN-jRCT2072220055招募中2 期
An investigator-initiated trial to investigate the utility of LUNAR-1 in colorectal cancer patients with resectable distant metastases - COSMOS-CRC-03
Oki Eiji0 个研究点目标入组 160 人开始时间: 2022年10月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.The patient was diagnosed with colorectal cancer based on histological diagnosis of the primary lesion.
- •2.The following metastatic lesions have been clinically diagnosed from colorectal cancer (regardless of whether they are synchronous or metachronous). Metastases involving multiple organs are also eligible.
- •1)lung metastasis (Less than 5 in preoperative diagnosis)
- •2)liver metastasis (any number)
- •3)peritoneal metastasis (Less than 5 in preoperative diagnosis)
- •4)extra-regional lymph node metastasis (Less than 3 in preoperative diagnosis)
- •5)ovarian metastasis
- •6)other metastases, such as adrenal or splenic metastases (confirm with coordinating physician prior to enrollment)
- •3.The distant metastases are diagnosed by one of following tests.
- •1)Chest CT (5 mm slices) (both plain and contrast-enhanced CT are acceptable)
- •2)Upper abdominal contrast-enhanced CT (5 mm slices) * or upper abdominal MRI (5 mm slices)
- •3)Pelvic contrast-enhanced CT (5 mm slices) * or pelvic MRI (5 mm slices)
- •*If the patient is allergic to contrast agent, plain CT is acceptable.
- •4.Surgical resection is planned for the primary and metastatic lesions. Distant metastases should be perfomed by one-stage surgery. However, two-stage surgery within 28 days is acceptable in cases of metastasis in the right or left lung. Either of the following cases are eligible.
- •1)R0 resection is planned for the both primary lesion and distant metastases. (Resection of the primary and metastatic lesions as a two-step surgery within 28 days is permitted. Resection of the primary tumor is performed first in the cases.)
- •2)R0 resection has been performed for the primary lesion, and the first R0 resection for a distant lesion is scheduled.
- •3)R0 resection has been performed for the primary and metastatic lesion, and the R0 resection for a distant lesion is scheduled.
- •5. Patients will be eligible only if the history of chemotherapy or radiotherapy for the primary or distant metastases meets either of the conditions 1) or 2) below.
- •1) Prior chemotherapy for the primary or metastatic lesion was performed, and at least 28 days have passed since the final dose of chemotherapy at the time of enrollment.
- •2) Preoperative radiotherapy was administered for the primary or previous metastatic lesion.
- •6.If metastases to the liver or lungs are present, the patient has no history of cryotherapy or thermocoagulation therapy such as radiofrequency cauterization (including concomitant administration at the time of resection of metastases to the liver).
- •7.Being aged 18 years or above at the time of obtaining written consent.
- •8.ECOG Performance Status (PS) of 0 or 1. For patients aged 75 years or above, only a PS 0 is acceptable.
- •9.The patient is able to have blood collected according to the Protocol for this Study after enrollment.
- •10.The patient has fulfilled all of the following test findings. (The latest test results within the period of 14 days before enrollment should be used. The day 1 week before the enrollment is acceptable)
- •1)Neutrophil count >= 1,500 / mm3
- •2)Platelet count >= 10 x 10^4 / mm3
- •3)GOT =<100 IU/L (If liver metastases are present, GOT =<150 IU/L)
- •4)GPT =< 100 IU/L (If liver metastases are present, GOT =<150 IU/L)
- •5)T. Bil =< 1.5 mg/dL
- •6)Cr =< 1.4 mg/dL
- •11.Written consent to participate in the study has been provided by the patient himself/herself.
排除标准
- •1.The patient has active multiple cancer (synchronus multiple cancers, and metachronus multiple cancers with a disease-free period of 5 years or less. However, patients with intraepithelial or intramucosal cancer in any organ that is determined to have been cured with localized therapy can be enrolled)
- •2.In the case of female patients, the patient is possibly pregnant or is breastfeeding.
- •3.The patient has concurrent interstitial pneumonia, pulmonary fibrosis or severe emphysema.
- •4.The patient has concurrent psychiatric disease or psychiatric symptoms determined to make it difficult for the patient to participate in the clinical trial.
- •5.The patient is receiving continuous systemic steroid therapy (oral or intravenous).
- •6.The patient has concurrent diabetes mellitus that is being treated with continuous insulin administration or is poorly controlled.
- •7.The patient has concurrent poorly controlled hypertension.
- •8.The patient has a history of one or more of the following: serious heart disease, cardiac failure, myocardial infarction within the past 6 months or angina attacks within the past 6 months.
- •9.Patients whom the PI or investigators decided as inappropriate for the clinical trial.
研究者
相似试验
尚未招募
不适用
A study to evaluate the safety of immune cell therapy in early transplant period of hematopoietic stem cell transplant recipientsKCT0004024The Catholic University of Korea, Seoul St. Mary's Hospital32
进行中（未招募）
2 期
The safety and efficacy of ALARM-TD-V1 for sleep-disordered breathingSleep-disordered breathingD020181Obstructive Sleep Apnea SyndromeJPRN-jRCT2052230034Sato Susumu40
已完成
不适用
An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)JPRN-UMIN000035926Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development40
尚未招募
不适用
A scientific trail to evaluate the effect of a 13 week long lifestyle change program, anchored in the science of yoga i.e Swasth Wellness Program (SWP), on the systolic blood pressure, in subjects who are not on any anti-hypertensive treatment.CTRI/2021/03/031779Mr Sundeep Kapalia
进行中（未招募）
1 期
Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopeciaAndrogenetic Alopecia Hamilton-Norwood IIIv-IV male patientsMedDRA version: 16.1Level: PTClassification code 10068168Term: Androgenetic alopeciaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2013-004130-15-DECharité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science12